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Introduction
Lurasidone is a second-generation antipsychotic 
(SGA), recently licensed for the treatment of 
schizophrenia in adults in the UK.1 Lurasidone is 
also approved for treating schizophrenia in adoles-
cents2 and depressive episodes in bipolar 1 in the 
United States.3 It acts as a potent antagonist at 
D2, 5HT2a, and 5HT7 receptors.4 Lurasidone has 
a comparatively benign metabolic side effect pro-
file, possibly related to a low affinity for H1 and 
5HT2c receptors,4 and has been recommended as 
an alternative when hoping to avoid metabolic 
adverse events or weight gain.5 Efficacy has been 
shown in a number of short-term randomized 
controlled trials (RCTs) and a double-blind 
extension study.6 However, in a comparative net-
work meta-analysis of RCTs, lurasidone was 
ranked as having a higher rate of drug discontinu-
ation than any other SGA currently available in 
the UK.7 Higher rates of all-cause discontinuation 
have been shown in direct comparison with risp-
eridone.8 So far, there has been limited explora-
tion of how lurasidone fares in clinical practice. 
One study has reported lower rates of discontinu-
ation with lurasidone compared with other SGAs 
when measuring health insurance administrative 
claims,9 but was unable to determine predictors of 
treatment continuation.
A prospective year-long follow-up of 
lurasidone use in clinical practice: factors 
predicting treatment persistence
Ian J. Osborne , Shubhra Mace and David Taylor
Abstract
Background: Our aim was to follow up patients prescribed lurasidone over 1 year to determine 
factors predicting treatment persistence.
Methods: We used noninterventional, observational, prospective follow up of patients 
consecutively prescribed lurasidone in a large inner-city NHS mental health trust. We also 
performed retrospective analysis of outcomes from patient case notes.
Results: Data were available for 69 patients consecutively prescribed lurasidone, of whom 
three (4%) were lost to follow up. Out of the 66 patients not lost to follow-up, 21 (32%) 
remained on lurasidone at 1 year. The main reasons for discontinuation were perceived 
ineffectiveness (49% of discontinuers) and adverse effects (36% of discontinuers), whilst 
a further seven refused all treatment. Median treatment time on lurasidone was 154 days 
(95% confidence interval (CI), 33–275). Patients who were not treatment-resistant had a 
substantially reduced risk of discontinuation, relative risk (RR) 0.18 [95% CI 0.08, 0.41,  
p < 0.001]. Medium doses (>37–74 mg) of lurasidone reduced the risk of discontinuation by 
75% [RR 0.25 (95% CI 0.11, 0.58, p = 0.001)]; high doses (>74–148 mg) reduced the risk of 
discontinuation by 86% [RR 0.14 (95% CI 0.06, 0.35, p < 0.001)]. Risk of discontinuation was 
approximately doubled when the reason for prescribing lurasidone was poor tolerability of 
prior treatment [RR 2.01 (95% CI 1.05, 3.85, p = 0.035)].
Conclusion: The likelihood of treatment continuation with lurasidone can be vastly improved 
by targeting individuals most likely to benefit and by using optimal doses.
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Although clinical trials can show the efficacy of 
antipsychotic treatment under specific controlled 
conditions, such conditions are unlikely to be rep-
licated in practice. This can lead to difficulties in 
precisely predicting real-life efficacy and in iden-
tifying patient subgroups that benefit from treat-
ment in practice. To our knowledge, the predictors 
of treatment continuation with lurasidone have 
not previously been determined elsewhere.
Procedure
Lurasidone was approved for use in our large 
inner-city NHS mental health trust in July 2014. 
Patients were not required to give informed con-
sent to the study; the recording of patient details 
and monitoring of outcomes for this study was 
approved by the trust’s Drug and Therapeutics 
Committee, the locally designated approval com-
mittee for all noninterventional prescribing out-
come surveys, and the analysis used anonymized 
clinical data. Information was sent to all prescrib-
ers, informing them that lurasidone could be pre-
scribed for suitable patients on submission of an 
initiation form. The form included details about 
the patient (age, diagnoses), current medication, 
inpatient/outpatient status, reasons for prescrib-
ing and the starting dose of lurasidone. Treatment 
initiation was an independent prescribing deci-
sion without restrictions and all patients received 
care as normal. Our standard method had previ-
ously been designated (by our local ethical com-
mittee) as not requiring ethical committee 
approval, since treatment was not affected by our 
method and because data were anonymized. 
Those viewing patient-specific data as part of the 
data collection process were clinicians who could 
have seen these data as part of their normal work-
ing practice.
All patients consecutively prescribed lurasidone 
between August 2014 and August 2015 were 
included in the study. Each patient prescribed 
lurasidone was added to a register and the data 
provided in the initiation form was later con-
firmed using electronic patient medical notes and 
pharmacy electronic records. Further information 
was also collected at baseline, including patient 
demographics and clinical data, such as the dura-
tion of current illness and previous antipsychotic 
trials (number and type). Prior use of clozapine 
was confirmed. We also scrutinized notes to find 
out whether clozapine had previously been con-
sidered, but ultimately, not prescribed. Prior clo-
zapine use or consideration of use was deemed to 
constitute evidence of treatment resistance. 
Aripiprazole is an already established treatment 
option with a low risk for metabolic side effects. 
Lurasidone might be considered as an alternative 
SGA in patients for whom aripiprazole has previ-
ously been ineffective or poorly tolerated. To 
examine the outcomes of patients who had previ-
ously discontinued aripiprazole, the reason for 
discontinuing aripiprazole was collected retro-
spectively. The highest dose of lurasidone reached 
by 1 year (in continuers) or prior to discontinua-
tion (in discontinuers) was also collected (termed 
simply as ‘dose’ for the purpose of this study). 
Doses were categorised into low (⩽37 mg), 
medium (>37–74 mg) and high (>74 mg) dose 
groups, on the basis that a dosing range would be 
a more practical predictor to include for prescrib-
ing purposes.
Outcomes were collected retrospectively at least 1 
year after the initiation date. All patient records 
were scrutinized for documented adverse effects 
(including when they first occurred in relation to 
the initiation date and the dose). When patients 
discontinued lurasidone, records were searched 
for the reasons for stopping treatment.
Statistical analysis
Baseline demographics and clinical data were 
summarized using descriptive statistics. 
Frequencies and percentages were calculated for 
categorical data. The main outcome of interest 
was time to discontinuation of lurasidone and this 
was determined as the date lurasidone was started 
until lurasidone was stopped or 1 year of treat-
ment, whichever came soonest, and estimated 
using a Kaplan–Meier survival curve. Thus, the 
primary outcome was a measure of treatment 
continuation, a widely used outcome measure in 
observational studies,10 which has previously 
been shown to strongly correlate to clinical 
improvement as measured by the Clinical Global 
Impression Scale.11,12 Patients were categorized 
as censored if they remained on treatment at 1 
year, including those who remained on lurasidone 
when lost to follow-up.
To determine significant variables on survival, 
log-rank tests were performed. If variables had a 
significant association with survival (p < 0.2) they 
were considered for inclusion in the multivariate 
analysis. Cox proportional hazard regression was 
performed to establish the most significant factors 
influencing discontinuation. The final model was 
IJ Osborne, S Mace et al.
journals.sagepub.com/home/tpp 119
selected based on the significance of the variable 
(p < 0.05) and the Akaike’s Information Criterion 
(AIC).13 Schoenfield residuals14 were plotted 
against time to assess for the proportional hazard 
assumption and Cox–Snell residual plots15 were 
used to assess goodness of fit. All tests were per-
formed using STATA version 13 (StataCorp LP, 
College Station, Texas, USA).
Results
Patient characteristics
Full demographic and clinical data were available 
for the first 69 patients prescribed lurasidone, 
presented in Table 1. There were significant rela-
tionships between discontinuation and diagnosis, 
evidence of treatment resistance, and the number 
of previous antipsychotics trialled (Table 1).
In total, eight patients were not receiving regular 
antipsychotics at lurasidone initiation (4 of whom 
were treatment naïve), 17 received olanzapine, 11 
aripiprazole, 10 quetiapine, 9 other oral atypicals, 
5 oral conventional drugs, and 2 depot antipsy-
chotics. Eight (12%) patients were receiving treat-
ment with clozapine, of whom seven started 
lurasidone to augment clozapine, and one switched 
to lurasidone due to adverse effects on clozapine. 
Overall, the antipsychotic prescribed before lurasi-
done was not associated with discontinuation.
As a secondary, post hoc analysis, we also dichoto-
mized outcome by prior treatment as either olan-
zapine or non-olanzapine. The median time on 
treatment for those switched from olanzapine (n 
= 17) was 89 days [95% confidence interval (CI), 
0–187]. Compared with those switched from 
other antipsychotics, there was no statistically sig-
nificant difference in time on treatment (χ2 = 
0.21, d.f. = 1, p = 0.645).
The reasons for switching to lurasidone are given 
in Table 2. Prior poor tolerability of the previous 
antipsychotic was significantly (p = 0.181) associ-
ated with discontinuation (Table 2). In total, 47 
(68%) patients had received aripiprazole at any 
point in their treatment history prior to starting 
lurasidone, of whom 33 (70%) discontinued ari-
piprazole due to perceived inefficacy, 11 (23%) 
due to adverse effects, and for 3 patients the rea-
sons were not recorded. Overall, the recorded rea-
son for discontinuing a previous aripiprazole trial 
was not significantly associated with lurasidone 
discontinuation (χ2 = 1.03, d.f. = 1, p = 0.310).
Discontinuation
The main outcome was continuation with lurasi-
done at 1 year. In total, 45 patients (65%) were 
known to have discontinued lurasidone at 1 year, 
and 3 (4%) were lost to follow up (all 3 left the 
trust). The remaining 21 patients (30%) were 
confirmed as completing 1 year of continuous 
treatment [21 of 66 (32%) of those not lost to 
follow-up]. Median survival time on lurasidone 
for the whole cohort was 154 days (95% CI, 33–
275) (Figure 1).
The most common reasons for discontinuation 
were perceived inefficacy in 22 patients (49%) 
and adverse effects in 16 (36%), whilst 7 (16%) 
refused all treatment with oral medications. After 
discontinuing lurasidone, 43 of 45 patients 
switched to an alternative antipsychotic. Overall, 
15 (33%) of discontinuing patients were switched 
to olanzapine, 9 (20%) clozapine, 6 (13%) ari-
piprazole, 5 (11%) quetiapine, 4 (9%) other oral 
atypicals, 3 (7%) depot antipsychotics, and 2 
(4%) oral conventional drugs. Two (4%) patients 
were not switched to an antipsychotic; one com-
menced a non-antipsychotic mood stabilizer, and 
one ceased all treatment.
Amongst patients all defined as treatment- 
resistant, 20 of 33 (60%) patients stopped because 
of inefficacy. Of the 26 treatment-resistant patients 
not using lurasidone for clozapine augmentation, 
24 (85%) discontinued treatment by 1 year.
Dose
The mean starting dose of lurasidone was 31 mg 
[standard deviation (SD) 13.0] and there was no 
statistical difference between those who contin-
ued and discontinued treatment (p = 0.808). 
Patients were categorized into low (⩽37 mg), 
medium (>37–74 mg), and high (>74 mg) dose 
groups, as presented in Table 3, according to the 
highest dose of lurasidone reached before out-
come. The dose of lurasidone was significantly 
associated with treatment discontinuation (Table 
3, Figure 2). Of those discontinuing lurasidone 
due to perceived inefficacy (n = 22), 6 (27%) 
patients received low doses of lurasidone, 6 (27%) 
medium doses, and 10 (45%) high doses.
Adverse effects
The adverse effects leading to lurasidone discon-
tinuation are summarized in Table 4. The most 
common adverse effects were acute movement 
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Table 1. Baseline characteristics.
Cohort characteristics Totala Continued 
(censored)
Discontinued χ2 (d.f.) p
n = 69 n = 24 n = 45  
n (%) n (%) n (%)
Gender  
 Male 35 (51) 13 (37) 22 (63) 0.041 (1) 0.839
 Female 34 (49) 11 (32) 23 (68)  
Age (years)  
 16–25 21 (30) 5 (24) 16 (76) 0.169 (2) 0.919
 26–49 32 (46) 12 (38) 20 (63)  
 ⩾50 16 (23) 7 (44) 9 (56)  
Ethnicity  
 White 27 (39) 11 (41) 16 (59) 0.443 (2) 0.801
 Black 26 (38) 8 (31) 18 (69)  
 Other 16 (23) 5 (31) 11 (69)  
Diagnosis  
 Schizophrenia 34 (49) 11 (32) 23 (68) 5.492 (3) 0.139
 Schizoaffective disorder 12 (17) 2 (17) 10 (83)  
 Bipolar affective disorder 18 (26) 7 (39) 11 (61)  
 Other 5 (7) 4 (80) 1 (20)  
Duration of illness (years)  
 0–4 35 (51) 12 (34) 23 (66) 3.373 (2) 0.185
 5–9 15 (22) 4 (27) 11 (73)  
 ≥10 19 (28) 8 (42) 11 (58)  
Care setting at initiation  
 Inpatient 47 (68) 15 (32) 32 (68) 0.091 (1) 0.763
 Outpatient 22 (32) 9 (41) 13 (59)  
Previous clozapine trial  
 Yes 23 (33) 7 (30) 16 (70) 1.359 (1) 0.244
 No 46 (67) 17 (37) 29 (63)  
Treatment resistance  
 Yes 33 (48) 8 (24) 25 (76) 4.594 (1) 0.033
 No 36 (52) 16 (44) 20 (56)  
No. of previous antipsychotics  
 0–2 25 (36) 13 (52) 12 (48) 7.527 (1) 0.006
 >2 44 (64) 11 (25) 33 (75)  
Started for clozapine 
augmentation
 
 Yes 7 (10) 4 (57) 3 (43) 0.484 (1) 0.487
 No 62 (90) 20 (32) 42 (68)  
aDistributions within the total group are shown as column percentages.
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Table 2. Reasons for switching to lurasidone.
Reason for switching Total Continued 
(censored)
Discontinued χ2 (d.f.) p
 n = 69 n = 24 n = 45  
n (%) n (%) n (%)
Prior poor effectiveness 34 (49) 13 (38) 21 (62) 0.18 (1) 0.671
Prior poor tolerability 25 (36) 6 (24) 19 (76) 1.79 (1) 0.181
Other, including patient choice 10 (14) 5 (50) 5 (50) 1.21 (1) 0.270
Figure 1. Kaplan–Meier plot showing the proportion of patients (with 95% confidence interval) prescribed 
lurasidone over time since treatment initiation.
CI, confidence interval.
Table 3. Dose of lurasidone prescribed (n = 69).
Dose range of lurasidone Total Continued 
(censored)
Discontinued χ2 (d.f.) p
 n = 69 n = 24 n = 45  
n (%) n (%) n (%)
Low dose (18.5–37 mg) 21 (30) 3 (14) 18 (86) 8.718 (2) 0.013
Medium dose (>37–74 mg) 23 (33) 9 (39) 14 (61)  
High dose (>74–148 mg) 25 (36) 12 (48) 13 (52)  
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disorders, reported on average 111 days after ini-
tiation at a mean dose of 34 mg (SD 21.6); 
akathisia/agitation 65 days after initiation at 44mg 
(SD 18.5); and insomnia 49 days after initiation 
at 31mg (SD 21.4). Of those patients discontinu-
ing lurasidone due to adverse effects (n = 16), 9 
(56%) received low doses, 6 (38%) medium 
doses, and 1 (6%) received high-dose treatment.
Predictors of discontinuation
The variables included in the Cox regression 
model included: patient diagnosis, duration of ill-
ness, whether or not there was evidence of treat-
ment resistance, the number of prior 
antipsychotics, the reason for initiation, and the 
dose of lurasidone. Three variables were signifi-
cantly associated with treatment discontinuation 
(Table 5). The results of the model estimated that 
not being treatment-resistant at initiation was 
associated with an 82% decrease in the hazard of 
discontinuing treatment compared with being 
treatment-resistant (p < 0.001). Prior poor toler-
ability of the antipsychotic prescribed immedi-
ately before lurasidone was significantly associated 
with an estimated 101% increase in the risk of 
discontinuation (p = 0.035). Medium and high 
doses of lurasidone were associated with a 75% 
and 86% decrease in the hazard of discontinuing 
treatment compared with low doses (p = 0.001, p 
< 0.001), respectively.
Figure 2. Kaplan–Meier plot showing the proportion of patients prescribed lurasidone over time since 
treatment initiation, by the dose of lurasidone.
Table 4. Adverse effects leading to lurasidone 
discontinuation (n = 16).
Adverse effect na
Acute movement disorderb 6
Akathisia/agitation 4
Insomnia 3
Nausea 2
Irritability 2
Unclear or unspecified 1
Abdominal pain 1
Sedation 1
Anxiety 1
Reduced appetite 1
Allergy 1
aSome patients reported more than one adverse effect.
bParkinsonism, n = 4; dystonia, n = 1; oculogyric crisis, 
n = 1.
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No other variable was statistically associated 
with discontinuation. The predicted estimates of 
time on lurasidone treatment at best and worse 
conditions are presented in Figure 3 using the 
multivariate model of predictors of treatment 
continuation and discontinuation.
Discussion
The main finding in this study of an early cohort 
prescribed lurasidone is that 65% discontinued 
treatment by 1 year. The majority of discontinu-
ers stopped treatment owing to perceived ineffi-
cacy, which might be explained by the unusually 
high proportion of treatment-resistant patients. 
Higher doses of lurasidone were a positive predic-
tive factor for treatment continuation. Treatment 
resistance and prior poor treatment tolerability 
were negative predictive factors. Outcomes for 
patients with a specific combination of moderat-
ing factors were predicted to be substantially 
improved: around 80% of patients without 
Table 5. Cox model regression results.
Variable Univariate Multivariate
 HR 95% CI p value HR 95% CI p value
No evidence of treatment resistance 0.531 0.294, 0.960 0.036 0.184 0.083, 0.407 <0.001
Prior poor tolerabilitya 1.492 0.825, 2.700 0.185 2.009 1.049, 3.845 0.035
Dose of lurasidone at outcomeb 0.017 <0.001
 Medium dosec 0.532 0.264, 1.075 0.079 0.254 0.112, 0.575 0.001
 High dosec 0.370 0.181, 0.755 0.005 0.142 0.058, 0.347 <0.001
aVersus other reasons for switching.
bp value for whole variable.
cVersus low doses.
HR, hazard ratio; CI, confidence interval.
Figure 3. Predicted estimates (using the Cox regression model) of time on lurasidone*.
*Multivariate regression estimates.
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treatment resistance that tolerated their prior 
treatment and received the higher doses of lurasi-
done would complete 1 year of treatment. The 
proportion of patients continuing at 1 year with 
treatment resistance who poorly tolerated their 
prior treatment and received the lower doses of 
lurasidone would be close to zero. Adverse effects 
were broadly in line with those previously docu-
mented in pooled study data.6
Our findings provide direction to improve treat-
ment outcomes with lurasidone, which begins 
with selecting patients most likely to benefit from 
treatment. There may be a temptation to prescribe 
new antipsychotics like lurasidone to treatment-
refractory patients (just under half of this early 
cohort had evidence of treatment resistance) who 
have not tolerated prior antipsychotics. Outcomes 
for these patients were poor. Continuation with 
treatment will likely be improved by using lurasi-
done in treatment-responsive patients. The ration-
ale for switching to lurasidone after prior poor 
treatment tolerability should be closely assessed. 
The main comparative advantage of lurasidone is 
an improved cardiometabolic side-effect profile, 
yet most of those switched due to prior poor toler-
ability (15 of 25) were for noncardiometabolic 
reasons. Most patients in this study were switched 
to lurasidone during inpatient admissions, and 
can reasonably be assumed to be in an acute phase 
of their illness. Better outcomes have been 
reported in nonacute-phase outpatients after 
switching lurasidone from a broad range of antip-
sychotics, with notable improvements in meta-
bolic parameters.16,17 Prior poor treatment 
tolerability may be a clinically useful reason for 
switching to lurasidone, particularly for those with 
cardiometabolic concerns.
Our findings also have value in optimizing the use 
of lurasidone. The use of lurasidone in doses 
higher than 37 mg (the recommended starting 
dose) strongly predicted treatment continuation. 
Higher doses did not appear to compromise toler-
ability; discontinuations due to adverse effects 
were in fact more common with lower doses (9 of 
18) than medium (6 of 14) and high (1 of 13) 
doses. Our observation is confounded by the fact 
that doses tend to increase as treatment persists; 
that is, continuation with treatment could be 
likely to predict higher doses. However, our find-
ings are in line recent RCT evidence that demon-
strated lurasidone early nonresponders benefit 
from dose escalation as early as 2 weeks after ini-
tiation without compromising tolerability.18 In 
patients switching to lurasidone from other antip-
sychotics, starting doses of 74 mg/day appear to 
be well tolerated.16 Patients in our low-dose group 
(18.5 mg to 37 mg/day) presumably reflect those 
who were not subjected to dose escalation after 
being commenced on the recommended starting 
dose of 37 mg/day. Continuation with treatment 
is likely to be improved by reviewing patients on 
lower doses of lurasidone (18.5–37 mg/day) for 
dose escalation where possible.
Limitations
This was a naturalistic observational study in 
which prescribing practices were not influenced. 
There were no controls on treatment differences 
between continuers and discontinuers. Although 
a number of potentially influencing factors were 
taken into account, there are others for which we 
have no information. Our results represent local 
outcomes in our particular clinical environment; 
one in which the use of lurasidone was not 
restricted. As such, the generalizability of our 
results in other healthcare systems is difficult to 
establish. The study sample size was relatively 
small; a larger sample could have allowed risk fac-
tors that are more moderately associated with 
treatment continuation to be demonstrated. 
There was no direct measure of clinical effective-
ness, although a clear relationship between treat-
ment continuation and clinical improvement has 
previously been demonstrated.10,11,19
Conclusion
The rates of treatment continuation with lurasi-
done are likely to be improved by targeting those 
most likely to benefit from treatment (patients 
without evidence of treatment-resistance) and by 
early dose optimization.
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